CriticalProkinetic, peripheral dopamine D2 receptor antagonist×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Pimozide also prolongs the QT interval, and ventricular arrhythmias and sudden death have been reported with it (pimozide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that such combinations raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions, and lists pimozide among the contraindicated antipsychotics (domperidone SmPC, AEMPS). The liver metabolises both drugs through CYP3A4, and pimozide also through CYP2D6 (domperidone and pimozide SmPCs, AEMPS). The documents give no data on how one drug changes the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With pimozide, ventricular tachycardia and ventricular fibrillation, sometimes fatal, cardiac arrest and sudden death have been reported (pimozide SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names pimozide. The Spanish pimozide SmPC contraindicates pimozide with drugs known to prolong the QT interval, without a closed list. According to its own SmPC, domperidone belongs to this group (domperidone and pimozide SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label also contraindicates pimozide with other QT-prolonging drugs (pimozide label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Pimozide is contraindicated with low potassium or magnesium and with clinically significant bradycardia (pimozide SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and repeat it during treatment. If QT prolongation, T-wave changes, U waves or arrhythmias appear, lower the pimozide dose or stop it. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). Correct low potassium before starting pimozide and keep it normal throughout treatment (pimozide FDA label). If domperidone and pimozide have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5